99 related articles for article (PubMed ID: 17230226)
1. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
2. Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways.
Zhao MN; Su L; Song F; Wei ZF; Qin TX; Zhang YW; Li W; Gao SJ
Acta Haematol; 2024; 147(3):310-324. PubMed ID: 37926079
[TBL] [Abstract][Full Text] [Related]
3. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
Pillinger G; Abdul-Aziz A; Zaitseva L; Lawes M; MacEwan DJ; Bowles KM; Rushworth SA
Sci Rep; 2015 Aug; 5():12949. PubMed ID: 26292723
[TBL] [Abstract][Full Text] [Related]
4. Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.
Arora D; Stopp S; Böhmer SA; Schons J; Godfrey R; Masson K; Razumovskaya E; Rönnstrand L; Tänzer S; Bauer R; Böhmer FD; Müller JP
J Biol Chem; 2011 Apr; 286(13):10918-29. PubMed ID: 21262971
[TBL] [Abstract][Full Text] [Related]
5. Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.
Yang T; Ke H; Liu J; An X; Xue J; Ning J; Hao F; Xiong L; Chen C; Wang Y; Zheng J; Gao B; Bao Z; Gong K; Zhang L; Zhang F; Guo S; Li QX
Sci Rep; 2024 Apr; 14(1):9032. PubMed ID: 38641704
[TBL] [Abstract][Full Text] [Related]
6. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling.
Anderson NR; Sheth V; Li H; Harris MW; Qiu S; Crossman DK; Kumar H; Agarwal P; Nagasawa T; Paterson AJ; Welner RS; Bhatia R
Leukemia; 2023 Mar; 37(3):560-570. PubMed ID: 36550214
[TBL] [Abstract][Full Text] [Related]
7. BRCC36 associates with FLT3-ITD to regulate its protein stability and intracellular signaling in acute myeloid leukemia.
Liu J; Isaji T; Komatsu S; Sun Y; Xu X; Fukuda T; Fujimura T; Takahashi S; Gu J
Cancer Sci; 2024 Apr; 115(4):1196-1208. PubMed ID: 38288901
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.
Yashar WM; Curtiss BM; Coleman DJ; VanCampen J; Kong G; Macaraeg J; Estabrook J; Demir E; Long N; Bottomly D; McWeeney SK; Tyner JW; Druker BJ; Maxson JE; Braun TP
Mol Cancer Res; 2023 Jul; 21(7):631-647. PubMed ID: 36976323
[TBL] [Abstract][Full Text] [Related]
9. FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.
Chu SH; Heiser D; Li L; Kaplan I; Collector M; Huso D; Sharkis SJ; Civin C; Small D
Cell Stem Cell; 2012 Sep; 11(3):346-58. PubMed ID: 22958930
[TBL] [Abstract][Full Text] [Related]
10. Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.
Takeda Y; Nakaseko C; Tanaka H; Takeuchi M; Yui M; Saraya A; Miyagi S; Wang C; Tanaka S; Ohwada C; Sakaida E; Yamaguchi N; Yokote K; Hennighausen L; Iwama A
Br J Haematol; 2011 Jun; 153(5):589-98. PubMed ID: 21492125
[TBL] [Abstract][Full Text] [Related]
11. Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.
Tabariès S; Annis MG; Hsu BE; Tam CE; Savage P; Park M; Siegel PM
Oncotarget; 2015 Apr; 6(11):9476-87. PubMed ID: 25823815
[TBL] [Abstract][Full Text] [Related]
12. Combining a QSAR Approach and Structural Analysis to Derive an SAR Map of Lyn Kinase Inhibition.
Naboulsi I; Aboulmouhajir A; Kouisni L; Bekkaoui F; Yasri A
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544914
[TBL] [Abstract][Full Text] [Related]
13. FLT3 inhibitors for the treatment of autoimmune disease.
Whartenby KA; Small D; Calabresi PA
Expert Opin Investig Drugs; 2008 Nov; 17(11):1685-92. PubMed ID: 18922105
[TBL] [Abstract][Full Text] [Related]
14. Inducible production of recombinant human Flt3 ectodomain variants in mammalian cells and preliminary crystallographic analysis of Flt3 ligand-receptor complexes.
Verstraete K; Remmerie B; Elegheert J; Lintermans B; Haegeman G; Vanhoenacker P; Van Craenenbroeck K; Savvides SN
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Mar; 67(Pt 3):325-31. PubMed ID: 21393836
[TBL] [Abstract][Full Text] [Related]
15. Mining of transcriptome identifies CD109 and LRP12 as possible biomarkers and deregulation mechanism of T cell receptor pathway in Acute Myeloid Leukemia.
Deepak Shyl ES; Malgija B; Iniyan AM; Mahendran R; Prakash Vincent SG
Heliyon; 2022 Oct; 8(10):e11123. PubMed ID: 36299526
[TBL] [Abstract][Full Text] [Related]
16. Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia.
Sahoo BK; Lin YC; Tu CF; Lin CC; Liao WJ; Li FA; Li LH; Mou KY; Roffler SR; Wang SP; Yeh CT; Yao CY; Hou HA; Chou WC; Tien HF; Yang RB
Haematologica; 2023 May; 108(5):1284-1299. PubMed ID: 36005562
[TBL] [Abstract][Full Text] [Related]
17. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo.
Spohr C; Poggio T; Andrieux G; Schönberger K; Cabezas-Wallscheid N; Boerries M; Halbach S; Illert AL; Brummer T
Leukemia; 2022 Apr; 36(4):970-982. PubMed ID: 34903841
[TBL] [Abstract][Full Text] [Related]
18. Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors.
Cucchi DGJ; Van Alphen C; Zweegman S; Van Kuijk B; Kwidama ZJ; Al Hinai A; Henneman AA; Knol JC; Piersma SR; Pham TV; Jimenez CR; Cloos J; Janssen JJWM
Hemasphere; 2021 Jul; 5(7):e606. PubMed ID: 34136754
[No Abstract] [Full Text] [Related]
19. SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis.
Voisset E; Brenet F; Lopez S; de Sepulveda P
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708273
[TBL] [Abstract][Full Text] [Related]
20. CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity.
Gutjahr JC; Bayer E; Yu X; Laufer JM; Höpner JP; Tesanovic S; Härzschel A; Auer G; Rieß T; Salmhofer A; Szenes E; Haslauer T; Durand-Onayli V; Ramspacher A; Pennisi SP; Artinger M; Zaborsky N; Chigaev A; Aberger F; Neureiter D; Pleyer L; Legler DF; Orian-Rousseau V; Greil R; Hartmann TN
Haematologica; 2021 Aug; 106(8):2102-2113. PubMed ID: 32616529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
